QuidelOrtho and Allo Hope Foundation Join Forces to Advance Education, Connection and Early Testing for Alloimmunized Pregnancies

Rhea-AI Summary

QuidelOrtho (NASDAQ:QDEL) and the Allo Hope Foundation announced a collaboration to improve care for maternal red blood cell alloimmunization. The partnership focuses on education, early testing and stronger connections between labs, clinicians and families.

Starting this summer, co-produced educational materials for lab technicians and families will be distributed via both organizations’ digital channels.

News Market Reaction – QDEL

+0.15%

17 alerts

+0.15% Session close to close

+12.9% Peak in 28 hr 2 min

$961.49M Market Cap

0.3x Rel. Volume

In the Jun 2 session, QDEL gained 0.15%, reflecting a mild positive market reaction. Argus tracked a peak move of +12.9% during that session. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights QuidelOrtho’s focus on maternal health by collaborating with Allo Hope ...

Analysis

This announcement highlights QuidelOrtho’s focus on maternal health by collaborating with Allo Hope Foundation to address alloimmunization and HDFN through education and early testing. It builds on recent podcasts and initiatives centered on prenatal and infectious disease diagnostics. Against a backdrop of earlier revenue declines and widened losses, investors may monitor how such partnerships support the company’s immunohematology and prenatal testing franchise, while tracking future earnings reports and product launches for evidence of financial impact and execution on its broader optimization plans.

Historical Context

5 past events · Latest: May 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 21	Educational podcast HDFN	Positive	+4.0%	Science Bytes episode on HDFN and maternal alloimmunization awareness.
May 20	Investor conferences	Positive	+3.8%	Announcement of participation in two June 2026 investor conferences.
May 05	Q1 2026 earnings	Negative	-6.0%	Weaker Q1 2026 results and lowered full-year guidance.
Apr 23	Educational podcast syphilis	Neutral	-5.5%	Science Bytes episode on U.S. syphilis trends and prenatal screening gaps.
Apr 20	LEX Diagnostics acquisition	Positive	+1.4%	Announcement of QuidelOrtho’s acquisition of LEX Diagnostics and VELO platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent company news, including podcasts, conferences and M&A, has generally seen price moves that align with the underlying sentiment, with earnings driving a notable negative reaction.

Recent Company History

Over recent months, QuidelOrtho has mixed softer fundamentals with ongoing strategic and educational initiatives. On Apr 20, it was highlighted as buyer of LEX Diagnostics, followed by an educational podcast on syphilis trends on Apr 23. First-quarter 2026 results on May 5 showed revenue declines and wider losses, prompting a negative reaction. Subsequent investor conference participation and an HDFN-focused podcast in late May drew modestly positive responses. Today’s collaboration on maternal alloimmunization and HDFN education extends this theme of diagnostics-driven maternal and prenatal care awareness.

Key Terms

maternal red blood cell alloimmunization, hemolytic disease of the fetus and newborn (HDFN), alloimmunized

3 terms

maternal red blood cell alloimmunization medical

"Maternal red blood cell alloimmunization is a serious, often misunderstood condition..."

A mother’s immune system mistakenly treats some of the baby’s red blood cells as foreign and makes antibodies that can cross the placenta and damage the baby’s blood. Think of it like a home security guard who misidentifies a household member as an intruder and triggers an alarm that harms the household; the result can require blood testing, monitoring, or medical treatment before or after birth. Investors track it because rates of this condition drive demand for diagnostic tests, preventive therapies, hospital care, and regulatory approvals that affect healthcare revenues and costs.

hemolytic disease of the fetus and newborn (HDFN) medical

"...destroy fetal and neonatal red blood cells, causing hemolytic disease of the fetus and newborn (HDFN)..."

Hemolytic disease of the fetus and newborn (HDFN) is a condition where a pregnant person’s immune system makes antibodies that cross the placenta and destroy the baby’s red blood cells, causing anemia and jaundice before or after birth; it often stems from blood-type incompatibility. For investors, HDFN matters because it creates demand for preventative screening, blood-matching, medical treatments and newborn care; changes in diagnosis, therapy approvals, or reimbursement can directly affect companies in diagnostics, obstetric and neonatal therapies, and blood products.

alloimmunized medical

"...helping ensure alloimmunized patients receive the early testing, accurate information..."

Alloimmunized describes a person who has developed immune proteins that recognize and attack foreign blood or tissue markers after exposure through transfusion, pregnancy, or transplant. For investors, alloimmunization matters because it increases demand for specialized compatible blood products, diagnostic tests, and tailored therapies, can complicate clinical trials and approvals, and may raise treatment costs—similar to a security system that now rejects many previously accepted keys, narrowing available medical options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, June 2, 2026 /PRNewswire/ -- QuidelOrtho, a global leader in diagnostic innovation, and the Allo Hope Foundation, a nonprofit dedicated to supporting families and clinicians managing maternal alloimmunization, announced a new collaboration focused on improving prenatal care through education, early testing and stronger connections between laboratory providers, clinicians and patients.

Maternal red blood cell alloimmunization is a serious, often misunderstood condition that can pose significant risks to the child during pregnancy. Red cell antibodies can cross the placenta and destroy fetal and neonatal red blood cells, causing hemolytic disease of the fetus and newborn (HDFN), a temporary but life-threatening condition that requires timely, specialized treatment. Many families struggle to find clear, early and actionable information, creating gaps in care that disproportionately affect underserved populations. This collaboration aims to change that.

Rooted in a shared purpose, QuidelOrtho and Allo Hope will jointly develop resources that elevate patient voices, increase awareness among healthcare providers and help ensure women receive informed, equitable prenatal testing and care from the very beginning.

"At QuidelOrtho, our mission is to advance diagnostics for a healthier future for all," said Bryan Hanson, Executive Vice President, Global Portfolio Management and Marketing, QuidelOrtho. "Through this collaboration with the Allo Hope Foundation, we are activating that mission in a meaningful new way, helping ensure alloimmunized patients receive the early testing, accurate information and compassionate support they deserve. This is the perfect moment to highlight how diagnostics can directly improve maternal health outcomes, especially for those who have historically been underserved."

The collaboration also reinforces a commitment to patient-centered authenticity.

"At Allo Hope, our work begins and ends with the patient experience," said Bethany Weathersby, Founder and Executive Director, Allo Hope Foundation. "Families facing alloimmunization often feel overwhelmed and isolated. By collaborating with QuidelOrtho, we're able to bring together clinical expertise, trusted diagnostics and lived experience to provide education that is both accurate and deeply human. We're excited to broaden awareness and reach more families earlier, with clarity, compassion, and the support needed, to make  survival the standard for children with HDFN."

Beginning this summer, QuidelOrtho and the Allo Hope Foundation will release a series of co-produced educational materials designed for both lab technicians and families.

These educational assets will be made available through both organizations' digital channels.

QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.

About QuidelOrtho Corporation

With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.

About the Allo Hope Foundation

The Allo Hope Foundation (AHF) serves families and clinicians globally navigating red cell alloimmunization and hemolytic disease of the fetus and newborn (HDFN). Led by patients with expertise in education, research, and clinical practice and guided by a multidisciplinary Medical Advisory Board, Patient Advisory Board, and Board of Directors, AHF believes survival from HDFN should be an expectation and global reality. AHF provides daily patient counsel for thousands of families, facilitates specialty referrals, conducts and publishes disease research and clinical practice guidelines, and raises global awareness through provider education and public health initiatives.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com 

Media Contact:
Stephanie Kleewein
Senior Corporate Communication and PR Manager
Media@QuidelOrtho.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-and-allo-hope-foundation-join-forces-to-advance-education-connection-and-early-testing-for-alloimmunized-pregnancies-302787974.html

SOURCE QuidelOrtho Corporation

FAQ

What did QuidelOrtho (QDEL) announce with the Allo Hope Foundation in June 2026?

QuidelOrtho announced a new collaboration with the Allo Hope Foundation to enhance education and early testing for alloimmunized pregnancies. According to QuidelOrtho, the partnership aims to connect laboratory providers, clinicians and patients to improve prenatal care for maternal red blood cell alloimmunization.

How does the QuidelOrtho and Allo Hope collaboration support alloimmunized pregnancies?

The collaboration supports alloimmunized pregnancies by developing educational resources for families and healthcare professionals. According to QuidelOrtho, these materials will elevate patient voices, raise provider awareness and promote informed, equitable prenatal testing and care from the earliest stages of pregnancy.

What is hemolytic disease of the fetus and newborn (HDFN) mentioned in the QuidelOrtho (QDEL) news?

HDFN is described as a temporary but potentially life-threatening condition caused when red cell antibodies destroy fetal or neonatal red blood cells. According to QuidelOrtho, it results from maternal red blood cell alloimmunization and requires timely, specialized treatment during pregnancy and after birth.

When will educational materials from the QuidelOrtho and Allo Hope Foundation partnership be available?

Educational materials from the partnership are expected to begin releasing in the summer of 2026. According to QuidelOrtho, these co-produced resources for lab technicians and families will be distributed through both organizations’ digital channels to broaden awareness and support earlier, informed care.

Why is the QuidelOrtho (QDEL) and Allo Hope Foundation partnership important for underserved populations?

The partnership targets care gaps that disproportionately affect underserved populations facing maternal alloimmunization. According to QuidelOrtho, many families struggle to access clear, early, actionable information, so the initiative emphasizes equitable prenatal testing, accurate education and compassionate support to improve maternal and neonatal health outcomes.